Details of the Drug

General Information of Drug (ID: DMVZLIB)

Drug Name
AHL
Synonyms AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark
Indication
Disease Entry ICD 11 Status REF
Hearing disorder AB50-AB57 Investigative [1]
Drug Type
siRNA drug
Cross-matching ID
TTD ID
D0T8EL

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P53 messenger RNA (TP53 mRNA) TT12KOD P53_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hearing disorder
ICD Disease Classification AB50-AB57
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P53 messenger RNA (TP53 mRNA) DTT TP53 7.90E-07 0.3 0.59
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27.